
Vir Biotech's Stock Soars and Plummets: A Rollercoaster Ride in the Pandemic
Shares of Vir Biotechnology plunged 43% after the company's trial for an influenza prophylaxis failed, causing the stock to drop to around $13.
All articles tagged with #influenza prophylaxis

Shares of Vir Biotechnology plunged 43% after the company's trial for an influenza prophylaxis failed, causing the stock to drop to around $13.